China's Plan to Exempt More Devices From Trials Will Save Companies Effort And Cost
This article was originally published in SRA
China's Food and Drug Administration is inviting feedback on a new batch of medium- and high-risk medical devices that it intends to exempt from having to undergo local clinical trials1. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market2.
Register for our free email digests: